Presage Biosciences
530 Fairview Avenue North, Suite 1000
Seattle
Washington
United States
Website: http://www.presagebio.com/
28 articles about Presage Biosciences
-
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
11/30/2023
Presage Biosciences has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.
-
Presage to Present at AACR 2023 - Core CIVO Technology Reveals Unexpected Effects of an Investigational Ubiquitination Inhibitor on Checkpoint Blockade
4/17/2023
Presage Biosciences will present at the Immunology, TME Minisymposium at the American Association for Cancer Research (AACR) 2023 Annual Meeting.
-
Presage Announces Collaboration with Pure Biologics to Investigate Oncology Agents in Early Development with CIVO® Technology
2/6/2023
Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced it has entered into a new research collaboration with Poland-based biopharmaceutical company Pure Biologics to evaluate two of Pure Biologics' very early stage assets in a Phase 0 intratumoral microdosing study.
-
Presage Completes First Phase 0 Clinical Study to Enable Simultaneous Evaluation of Investigational Immuno-Oncology Drug Combinations Directly in Patient Tumors
11/28/2022
Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced completion of a first-of-its-kind Phase 0 clinical study utilizing its CIVO® (Comparative In Vivo Oncology) multiplexed microdosing technology.
-
Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics
3/2/2021
Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology intratumoral microdosing platform, announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.
-
Presage Announces New, Multi-Project Collaboration with Takeda for Phase 0 Studies of Novel Cancer Agents with CIVO® Technology
9/9/2020
Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology intratumoral microdosing platform, announced a new research collaboration with Takeda Pharmaceutical Company Limited that will utilize CIVO to evaluate multiple investigational oncology agents and combinations in Phase 0 trials.
-
Presage Receives FDA Clearance of First IND Application for Trial to Evaluate Investigational Oncology Agents with CIVO™ Technology
1/9/2020
Presage Biosciences, a biotechnology company pioneering a new cancer drug development approach using its CIVO® intratumoral microdosing platform, announced today that the U.S. Food and Drug Administration (FDA) has approved its first Exploratory Investigational New Drug (IND) application for a Phase 0 study utilizing its CIVO platform.
-
Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology
8/27/2019
Presage Biosciences announced it has entered into a research collaboration with Bristol-Myers Squibb Company to evaluate early stage oncology targets in Phase 0 trials.
-
Presage Announces Collaboration with Celgene to Investigate Novel Agents with CIVO™ Technology
5/2/2019
Research agreement to support Phase 0 tumor microdosing studies
-
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
-
Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
7/17/2018
Nathan Caffo to transition to Senior Corporate Advisor
-
Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.
-
Presage Biosciences Awarded Debut Grant From The Mark Foundation For Cancer Research To Support Immuno-Oncology Applications Of CIVO, An Intratumoral Microdosing Platform
9/25/2017
-
San Diego's MEI Pharma Forges $184 Million Cancer Deal With Presage Biosciences
9/6/2017
-
Presage Biosciences Appoints David Johnson To Board Of Directors
6/6/2016
-
Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition By Voruciclib And Proteasome Inhibitors Superior To Single Agents In Model Of Triple Negative Breast Cancer
4/19/2016
-
Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition By Voruciclib And Proteasome Inhibitors Superior To Single Agents In Model Of Triple Negative Breast Cancer
4/19/2016
-
Presage Biosciences Extends Research Collaboration With Takeda To Discover Novel Cancer Drug Combinations
4/14/2016
-
Presage Biosciences Appoints Oncology Experts To Newly Created Medical Advisory Panel
1/11/2016
-
Presage Biosciences In-Licenses Clinical Stage Drug Program
11/24/2015